Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment
To provide early access to tipranavir and evaluate the safety and tolerance of tipranavir combined with low dose of ritonavir in patients with progressive, HIV-1 disease who have failed or are intolerant to currently approved treatments for HIV infection, who are unable to participate in another tipranavir controlled clinical trial and have an urgent need for anti-HIV treatment.
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||Emergency Use Program for Highly Treatment-Experienced HIV+ Patients|
|Contact: Boehringer Ingelheim Call Centeremail@example.com|
Show 141 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim Pharmaceuticals|